.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01D_CytotoxicAntibioticsAndRelatedSubstances.L01DB06_Idarubicin.Idarubicin .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01D_CytotoxicAntibioticsAndRelatedSubstances.L01DB06_Idarubicin.Idarubicin| name: | Idarubicin | |
| ATC code: | L01DB06 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 12 | mg |
| volume of distribution: | 41.1 | L |
| clearance: | 38.1 | L/h |
| other parameters in model implementation | ||
Idarubicin is an anthracycline antineoplastic agent used primarily in the treatment of acute myeloid leukemia (AML) in adults and children. It is a cytotoxic antibiotic that intercalates into DNA, disrupting DNA replication and repair. Idarubicin is approved for medical use in several countries and remains a standard treatment in combination chemotherapy regimens for hematological malignancies.
Pharmacokinetic parameters in adult patients with acute leukemia following intravenous administration. Population PK studies most frequently report two-compartmental models.
Bouabdallah, R, et al., & Fenaux, P (1999). A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients. Leukemia 13(10) 1491–1496. DOI:10.1038/sj.leu.2401522 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10516747